CSL Behring and Seattle Children’s Research Institute recently announced a partnership to develop treatment options for two, rare, life-threatening primary immunodeficiency diseases.
Initially, the alliance will develop treatment options for Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia.
“Expanding our gene therapy portfolio into an area of immunology well known to CSL Behring exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients’ lives,” said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring.
Read more about the partnership in this press release and in coverage from the Philadelphia Business Journal: CSL Behring enters into gene therapy collaboration with top children’s research institute.
